Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI (IRON-RLS)

11 de setembro de 2026 atualizado por: University Hospital, Montpellier

Intravenous Iron in the Management of Drug-resistant Restless Legs Syndrome: a Randomized Controlled Delayed-start Trial. IRON-RLS

The pathophysiology of restless legs syndrome (RLS) is not well understood: it is thought to involve intracerebral iron deficiency and dopaminergic dysregulation.

This study aims to evaluate the use of intravenous ferric carboxymaltose in patients with restless legs syndrome (RLS).

This study plans to include individuals with RLS, who will be divided into two groups:

  • One group will receive intravenous iron immediately after the baseline polysomnography
  • The second group will receive intravenous iron 3 months after randomization. In total, participants will be followed for 6 months, during which time they will be required to complete questionnaires regularly, undergo blood draws, and have two polysomnography tests.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

66

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Age ≥ 18 years;
  • Weight ≥ 50 kg;
  • Drug-resistant RLS;
  • Severe to very severe RLS (IRLSSG-Q score > 20), persistent or recurrent for more than one month;
  • Treatment with dopamine agonists without exceeding the recommended doses (ropinirole ≤ 2 mg/day, pramipexole ≤ 0.54 mg/day, rotigotine ≤ 3 mg/day);
  • Treatment with dopamine agonists and/or α2δ ligands and/or opioids that has been stable for at least 3 months;
  • In cases of sleep apnea syndrome, treatment with continuous positive airway pressure (CPAP);
  • Participants were required to be fluent in spoken and written French, be enrolled in a health insurance plan, agree to the automated processing of anonymized confidential data, and have provided written, informed consent for the study.

Exclusion Criteria:

  • Iron supplementation (oral or intravenous) within 3 months prior to enrollment and throughout the study period
  • Serum ferritin < 50 µg/L or > 300 µg/L;
  • Transferrin saturation < 20% or > 45%;
  • Hemochromatosis;
  • RLS augmentation syndrome ;
  • Treatment with neuroleptics or antidepressants;
  • Allergy to iron;
  • Severe infectious or inflammatory disease within the past 3 months;
  • RLS associated with chronic kidney disease, pregnancy, or a clinically significant neurological or psychiatric disorder;
  • Severe sleep apnea syndrome (AHI > 30/h) that is untreated, or in cases where treatment is refused or has failed;
  • Known allergy, inflammatory, or immune disorder;
  • History of severe asthma, eczema, or any other atopic allergy;
  • Pregnancy or breastfeeding;
  • Also excluded are patients participating in another research study, those deprived of their liberty by judicial or administrative order, those living in a medical facility, those subject to a legal protection order, or those from whom consent could not be obtained.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Immediate treatment
The treatment will be administered at at baseline (V1), immediately after the baseline polysomnography
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
Comparador Ativo: Delayed-onset treatment
The treatment will be administered at 12 weeks
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
IRLSSG-Q score
Prazo: From Day 0 to Week 12
IRLSSG-Q : International Restless Legs Study Group Severity Rating Scale allows for the quantification of the severity of restless legs syndrome
From Day 0 to Week 12

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Periodic Limb Movements during Sleep (PLMS) index
Prazo: From V1 (Day 0) to V5 (week 24)
The PLMS Index measures the average number of involuntary leg movements per hour of sleeping during polysomnography. 15 or more per hour: Considered abnormal for adults and may suggest a condition called Periodic Limb Movement Disorder (PLMD) if it disrupts your sleep.
From V1 (Day 0) to V5 (week 24)
Total sleep time
Prazo: From day 0 to week 24
Total sleep time measured in minutes during polysomnography.
From day 0 to week 24
Sleep latency
Prazo: From Day 0 to week 24
Length of time in minutes it takes to transition from full wakefulness to the lightest stage of sleep after the lights are turned off.
From Day 0 to week 24
Sleep time at stage 1-2 during polysomnography
Prazo: From Day 0 to week 24
Time spent in stage 1-2 sleep measured in hours and minutes during polysomnography
From Day 0 to week 24
Sleep time at stage 3 during polysomnography
Prazo: From Day 0 to week 24
Time spent in stage 3 sleep measured in hours and minutes during polysomnography
From Day 0 to week 24
Micro-awakenings index (MAI)
Prazo: From Day 0 to week 24
The Micro-awakenings index measures the number of brief awakenings that the person does not notice per hour of sleep.
From Day 0 to week 24
Apnea-hypopnea index (AHI)
Prazo: From Day 0 to week 24
The apnea-hypopnea index (AHI) measures the average number of interruptions or reductions in breathing per hour of sleep to assess the severity of sleep apnea.
From Day 0 to week 24
Average arterial oxygen saturation (SaO2)
Prazo: From Day 0 to Week 24
The unit of measurement for SaO2 is the percentage (%).
From Day 0 to Week 24
Oxygen desaturation index (IDO)
Prazo: From Day 0 to week 24
The oxygen desaturation index (IDO) measures the number of significant drops in blood oxygen levels per hour of sleep.
From Day 0 to week 24
Serum ferritin
Prazo: From Day 0 to week 24
From Day 0 to week 24
Transferrin saturation coefficient
Prazo: From Day 0 to Week 24
From Day 0 to Week 24
Epworth Sleepiness Scale (ESS)
Prazo: From Day 0 to Week 24
A measure of excessive daytime sleepiness that quantifies the impact of the condition on alertness throughout the day. Eight everyday situations are rated (for example, watching television, riding as a passenger in a car, sitting quietly in a public place). Each situation is scored from 0 to 3 based on the likelihood of falling asleep. Total score 0-24; a score of ≥10 suggests excessive sleepiness
From Day 0 to Week 24
European Quality of Life 5 Dimensions (EQ-5D)
Prazo: From Day 0 to Week 24
EQ-5D: this self-administered questionnaire assesses five dimensions (mobility, daily activities, self-care, pain/discomfort, anxiety/depression) as well as overall health status on a visual scale from 0 to 100
From Day 0 to Week 24
Clinical Global Impression (CGI)
Prazo: From Day 0 to Week 24
The clinician's overall assessment of the illness, including CGI-S (severity) and CGI-I (change). 7-point scale: CGI-S 1 = normal, 7 = extremely ill; CGI-I 1 = markedly improved, 7 = markedly worsened
From Day 0 to Week 24
Patient Global Impression (PGI)
Prazo: From Day 0 to Week 24
Patient's overall perception of the severity of their illness or change; a simple 7-point scale, self-reported. A high score is associated with patients perceiving their symptoms as severe
From Day 0 to Week 24
Beck Depression Inventory-II (BDI-II)
Prazo: From Day 0 to Week 24
BDI-II: a self-administered questionnaire consisting of 21 items that assess the severity of depressive symptoms over the past two weeks; score range: 0-63; thresholds: 0-13 (mild), 14-19 (moderate), 20-28 (severe), ≥29 (severe)
From Day 0 to Week 24
Augmentation Severity Rating Scale (ASRS)
Prazo: From Day 0 to Week 24
A 7-item self-administered questionnaire used to quantify the severity of the augmentation syndrome in patients treated with dopamine agonists. It assesses the worsening or early onset of RLS symptoms and their impact on sleep and daily activities
From Day 0 to Week 24
Insomnia Severity Index (ISI)
Prazo: From Day 0 to week 24
To assess the severity of the patient's insomnia, taking into account both the quantity and quality of sleep, as well as its impact on daily functioning (fatigue, concentration, mood). A 7-item self-report questionnaire scored from 0 to 4, with a total score of 0-28; 0-7 indicates no insomnia, 8-14 mild, 15-21 moderate, and 22-28 severe insomnia
From Day 0 to week 24

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de outubro de 2026

Conclusão Primária (Estimado)

1 de abril de 2029

Conclusão do estudo (Estimado)

1 de outubro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

28 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de setembro de 2026

Primeira postagem (Real)

16 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever